An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 5700 participants.

Also called NCT07517263

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,700 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07517263
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong SAR China, Hungary, Iceland, India, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07517263. Allocation not applicable; no masking; primary purpose treatment. Start 2026-05-11 (actual); primary completion 2030-01-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Condition
Cardiovascular Disease and Lipoprotein(a)
Intervention (Drug)
Pelacarsen (TQJ230)
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07517263
Content hash
eb2bc18dcc794e68100dcba772b8b2cde75faf39e62cf993b25ed693dac87915